- Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Pennell, D.J., Porter, J.B., Cappellini, M.D., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C.K., Viprakasit, V., Elalfy, M.S., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., Taher, A. Haematologica (2012)